Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

NexLife vs Queen RX

NexLife
Graded #139

Higher grade

vs+2.4000000000000057
Queen RX
Graded #192

Lower grade

The verdict

NexLife takes it — 68.7/100 to 66.3/100.

NexLife grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NexLife is a LegitScript-certified telehealth platform offering compounded semaglutide (from $145/mo) and compounded tirzepatide (from $186/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +6
71
77
Dose & formulationNexLife +7
64
57
Clinical oversightNexLife +20
89
69
Labs & monitoringEven
53
53
FulfillmentQueen RX +8
67
75
Contract termsQueen RX +6
55
61
NexLife · left barQueen RX · right bar

The numbers

MetricNexLifeQueen RX
WeighScore68.7/10066.3/100
GradeCC
Scorecard rank#139#192
Semaglutide$165/mo (compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$215/mo (compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
NexLife

Graded #139 · C

Strengths

  • LegitScript certified platform
  • Works exclusively with LegitScript-certified, NABP-accredited pharmacies — strongest pharmacy trust signal in the dataset
  • Both semaglutide and tirzepatide at competitive pricing
  • Semaglutide from $145/mo on the 12-month plan ($165/mo month-to-month) - among the lowest in the dataset

Where it loses points

  • State availability not publicly disclosed
  • Compounded only — no brand-name options
  • Also covers hormone optimization and longevity
  • Lowest advertised rates ($145 sema / $186 tirz) require a 12-month plan commitment
Queen RX

Graded #192 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard